Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

ImmVira Opens In-House Production Facility for Oncolytic Viruses

publication date: Jul 23, 2021

ImmVira, a Shenzhen oncolytic virus company, opened its pilot-scale production line for next-gen oncolytic viruses with capacity for Phase I/II clinical trials. The company said its strategy combines in-house manufacturing with CDMO, allowing ImmVira to innovate on CMC techniques and improvements in production efficiency. ImmVira's lead product, MVR-T3011, is a genetically modified oncolytic herpes simplex virus that includes two exogenous genes -- PD-1 antibody and IL-12 -- to enhance the immune response. One month ago, ImmVira dosed the first patients in a China/US Phase II trial of MVR-T3011. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital